Bicara Therapeutics Inc. Common Stock
NASDAQ: BCAX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Claire Mazumdar Clemon
- Employees
- 55
- Headquarters
- Boston, United States
- IPO year
- 2024
- Market cap
- $1.4B
- Website
- https://www.bicara.com
Loading BCAX…
Loading profile data…Frequently asked questions about BCAX
What does Bicara Therapeutics Inc. Common Stock (BCAX) do?
Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle sol...
Where does BCAX trade?
Bicara Therapeutics Inc. Common Stock (BCAX) trades on the NASDAQ Global Market.
What sector is BCAX in?
Bicara Therapeutics Inc. Common Stock (BCAX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Bicara Therapeutics Inc. Common Stock?
Claire Mazumdar Clemon is the chief executive officer of Bicara Therapeutics Inc. Common Stock (BCAX).
Where is Bicara Therapeutics Inc. Common Stock headquartered?
Bicara Therapeutics Inc. Common Stock is headquartered in United States.
Does BCAX pay a dividend?
Bicara Therapeutics Inc. Common Stock (BCAX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did BCAX go public?
Bicara Therapeutics Inc. Common Stock (BCAX) completed its initial public offering in 2024.